BIOMARIN PHARMACEUTICAL INC

BioMarin’s recent earnings beat, robust pipeline, and growing institutional support signal strong upside for specialty pharma investors.

Biomarin Pharmaceutical (BMRN) trades down 2.2% but analysts remain bullish, citing strong R&D in rare disorders and a robust pipeline that could boost long‑term growth.

Explore Biomarin Pharmaceutical’s latest stock performance, 24‑hour gains, key metrics, and biotech insights for savvy investors.